Optical electrophysiology for probing function and pharmacology of voltage-gated ion channels

Hongkang Zhang, Elaine C. Reichert, Adam E. CoheneLife 2016 · DOI

TL;DR

This paper introduces "Optopatch," a novel all-optical electrophysiology technique that uses light to both stimulate and measure ion channel activity. This method allows for high-throughput screening of drug effects on voltage-gated sodium channels (Nav1.7), offering a faster and more scalable alternative to traditional patch-clamp methods while maintaining high accuracy.

What Problem Does This Paper Address?

Understanding the precise function and drug interactions of voltage-gated ion channels is crucial for developing new therapeutics, especially for conditions like chronic pain mediated by Nav1.7. Traditional methods like patch-clamp electrophysiology, while accurate, are slow, labor-intensive, and not well-suited for high-throughput screening of large compound libraries. This limits the pace of drug discovery. The challenge is to develop a method that can accurately probe ion channel behavior, including complex state-dependent drug interactions, in a format that is both fast and scalable.

Methods

The core innovation is the "Optopatch" system, which combines optogenetics with genetically encoded voltage sensors.

  • Optogenetic Stimulation: A light-activated channelrhodopsin variant (CheRiff) is used to depolarize cells upon blue light stimulation. This triggers action potentials in engineered cells expressing specific ion channels.
  • Optical Readout: A red-shifted voltage indicator protein (QuasAr2) is used to report changes in membrane potential through fluorescence. This allows for non-invasive, real-time monitoring of cellular electrical activity.
  • Engineered Cell Lines: HEK293 cells were engineered to stably express Nav1.7 channels, along with CheRiff and QuasAr2. An inward rectifier potassium channel (Kir2.1) was also expressed to maintain a hyperpolarized resting potential, priming the Nav1.7 channels for activation.
  • Protocol Mimicry: The authors developed sophisticated light-pulse protocols to mimic traditional voltage-clamp experiments, including prepulses, recovery intervals, and test pulses, enabling the study of state-dependent drug binding and channel kinetics.
  • High-Throughput Screening: The system was adapted for use with 384-well plates, allowing for automated scanning and analysis of large compound libraries.

Datasets

The primary "dataset" in this paper is the screening of a library of 320 FDA-approved compounds against Nav1.7 channels. The authors also generated and characterized engineered HEK cell lines expressing specific ion channels (Nav1.7, Nav1.5, Kv4.3) and optogenetic tools.

Key Insights and Ideas

  • All-Optical Electrophysiology is Viable: The paper demonstrates that a fully optical approach can accurately recapitulate complex electrophysiological measurements, including voltage-clamp protocols and state-dependent pharmacology.
  • High-Throughput Screening for Ion Channels: Optopatch provides a powerful platform for screening large numbers of compounds for their effects on ion channels, significantly accelerating drug discovery.
  • State-Dependent Drug Action is Quantifiable: The technique successfully revealed state-dependent inhibition of Nav1.7 by drugs like amitriptyline and PF-04856264, highlighting the importance of voltage history in drug efficacy.
  • Nav1.7 Specificity is Challenging: The screen showed that many compounds that affect Nav1.7 also affect other Nav isoforms (like Nav1.5), underscoring the difficulty in finding truly subtype-specific analgesics.
  • Beyond Sodium Channels: The authors show preliminary success in adapting the platform for potassium channels (Kv4.3), suggesting broader applicability.

Key Results

  • Accurate Protocol Mimicry: Optopatch successfully reproduced voltage-clamp protocols to study activation, inactivation, and drug block of Nav1.7.
  • State-Dependent Drug Effects: Amitriptyline showed a significant difference in IC50 values depending on the prepulse duration (11.7 µM at 20 ms vs. 1.6 µM at 500 ms), consistent with patch-clamp data. PF-04856264's inhibition was strongly dependent on resting membrane potential.
  • High-Throughput Screen Performance: A pilot screen of 320 FDA-approved compounds identified hits with close concordance to patch-clamp measurements. The assay demonstrated a Z' factor of 0.57, indicating its suitability for high-throughput screening.
  • Kv4.3 Blockade: The platform was adapted to study Kv4.3, showing dose-dependent inhibition by heteropoda toxin 2 (HpTx2) with an IC50 of 252 nM.

Limitations and Future Work

  • Semi-Quantitative Voltage Control: While the optical readout is precise, the voltage control via light stimulation is semi-quantitative compared to direct voltage clamping. This is mitigated by averaging over many cells and using robust analysis protocols.
  • Expression Variability: While addressed by averaging, variations in optogenetic actuator and reporter expression levels between cells can still be a factor.
  • Limited Throughput (Current Implementation): The current implementation involves serial measurements of individual wells, limiting throughput. However, the authors suggest that parallelization and denser well formats could significantly increase throughput.
  • Off-Target Effects: While the study included checks for off-target effects on Kir2.1, CheRiff, and QuasAr2, it remains a potential concern for novel compounds.
  • Future Work: The authors suggest adapting the platform for other ion channel families (e.g., calcium channels) and exploring red-shifted voltage-sensitive dyes for improved spectral separation from optogenetic actuators. Further development of parallelized measurement systems is also envisioned.

Summary updated

Abstract

Voltage-gated ion channels mediate electrical dynamics in excitable tissues and are an important class of drug targets. Channels can gate in sub-millisecond timescales, show complex manifolds of conformational states, and often show state-dependent pharmacology. Mechanistic studies of ion channels typically involve sophisticated voltage-clamp protocols applied through manual or automated electrophysiology. Here, we develop all-optical electrophysiology techniques to study activity-dependent modulation of ion channels, in a format compatible with high-throughput screening. Using optical electrophysiology, we recapitulate many voltage-clamp protocols and apply to Nav1.7, a channel implicated in pain. Optical measurements reveal that a sustained depolarization strongly potentiates the inhibitory effect of PF-04856264, a Nav1.7-specific blocker. In a pilot screen, we stratify a library of 320 FDA-approved compounds by binding mechanism and kinetics, and find close concordance with patch clamp measurements. Optical electrophysiology provides a favorable tradeoff between throughput and information content for studies of NaV channels, and possibly other voltage-gated channels.
BibTeX
@inproceedings{zhang2016optical,
  author = {Hongkang Zhang and Elaine C. Reichert and Adam E. Cohen},
  title = {{Optical electrophysiology for probing function and pharmacology of voltage-gated ion channels}},
  booktitle = {eLife},
  year = {2016},
  doi = {10.7554/elife.15202},
}
Figure